AIM: To investigate whether cisplatin (DDP) enhances the anti-tumor activity of cytokine- induced killer (CIK) cells in a murine colon adenocarcinoma model. METHODS: Tumor size and weight served as indicators of therapeutic response. Immunohistochemistry was performed to observe intratumoral lymphocyte infiltration and tumor microvessel density. Changes in the percentage of regulatory T (Treg) cells within the spleens of tumor-bearing mice preconditioned with DDP were monitored using flow cytometry. RESULTS: A marked T cell-dependent, synergistic anti-tumor effect of the combined therapy was observed (1968 ± 491 mm³ vs 3872 ± 216 mm³; P = 0.003). Preconditioning chemotherapy with DDP augmented the infiltration of CD3+ T lymphocytes into the tumor mass and reduced the percentage of both intratumoral and splenic Treg cells. CONCLUSION: Preconditioning with DDP markedly enhances the efficacy of adoptively transferred CIK cells, providing a potential clinical modality for the treatment of patients with colorectal cancer.
AIM: To investigate whether cisplatin (DDP) enhances the anti-tumor activity of cytokine- induced killer (CIK) cells in a murinecolon adenocarcinoma model. METHODS:Tumor size and weight served as indicators of therapeutic response. Immunohistochemistry was performed to observe intratumoral lymphocyte infiltration and tumor microvessel density. Changes in the percentage of regulatory T (Treg) cells within the spleens of tumor-bearing mice preconditioned with DDP were monitored using flow cytometry. RESULTS: A marked T cell-dependent, synergistic anti-tumor effect of the combined therapy was observed (1968 ± 491 mm³ vs 3872 ± 216 mm³; P = 0.003). Preconditioning chemotherapy with DDP augmented the infiltration of CD3+ T lymphocytes into the tumor mass and reduced the percentage of both intratumoral and splenic Treg cells. CONCLUSION: Preconditioning with DDP markedly enhances the efficacy of adoptively transferred CIK cells, providing a potential clinical modality for the treatment of patients with colorectal cancer.
Authors: Jingting Jiang; Ning Xu; Changping Wu; Haifeng Deng; Mingyang Lu; Min Li; Bin Xu; Jun Wu; Rongchao Wang; Jun Xu; Peter Nilsson-Ehle Journal: Anticancer Res Date: 2006 May-Jun Impact factor: 2.480
Authors: Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg Journal: J Clin Oncol Date: 2005-04-01 Impact factor: 44.544
Authors: Anita E M Dirkx; Mirjam G A oude Egbrink; Karolien Castermans; Daisy W J van der Schaft; Victor L J L Thijssen; Ruud P M Dings; Lucy Kwee; Kevin H Mayo; John Wagstaff; Jessica C A Bouma-ter Steege; Arjan W Griffioen Journal: FASEB J Date: 2006-04 Impact factor: 5.191
Authors: Jun Ren; William R Gwin; Xinna Zhou; Xiaoli Wang; Hongyan Huang; Ni Jiang; Lei Zhou; Pankaj Agarwal; Amy Hobeika; Erika Crosby; Zachary C Hartman; Michael A Morse; Kevin H Eng; H Kim Lyerly Journal: Oncoimmunology Date: 2016-12-07 Impact factor: 8.110
Authors: Ya Hong Yuan; Chun Fang Zhou; Jiang Yuan; Li Liu; Xing Rong Guo; Xiao Li Wang; Yan Ding; Xiao Nan Wang; Dong Sheng Li; Han Jun Tu Journal: Oncol Lett Date: 2016-09-09 Impact factor: 2.967